PDF(Pubmed)
Abstract：
The current research investigated the use of gelatin nanoparticles (GNPs) for enhancing the cytotoxic effects of nivolumab, an immune checkpoint inhibitor. The unique feature of GNPs is their biocompatibility and functionalization potential, improving the delivery and the efficacy of immunotherapeutic drugs with fewer side effects compared to traditional treatments. This exploration of GNPs represents an innovative direction in the advancement of nanomedicine in oncology. Nivolumab-loaded GNPs were prepared and characterized. The optimum formulation had a particle size of 191.9 ± 0.67 nm, a polydispersity index of 0.027 ± 0.02, and drug entrapment of 54.67 ± 3.51%. A co-culture experiment involving A549 target cells and effector Jurkat cells treated with free nivolumab solution, and nivolumab-loaded GNPs, demonstrated that the latter had significant improvements in inhibition rate by scoring 87.88 ± 2.47% for drug-loaded GNPs against 60.53 ± 3.96% for the free nivolumab solution. The nivolumab-loaded GNPs had a lower IC50 value, of 0.41 ± 0.01 µM, compared to free nivolumab solution (1.22 ± 0.37 µM) at 72 h. The results indicate that administering nivolumab-loaded GNPs augmented the cytotoxicity against A549 cells by enhancing effector Jurkat cell activity compared to nivolumab solution treatment.
摘要：
目前的研究调查了使用明胶纳米颗粒（GNPs）来增强纳武单抗的细胞毒性作用，一种免疫检查点抑制剂.GNP的独特特征是它们的生物相容性和功能化潜力，与传统治疗相比，改善免疫治疗药物的递送和疗效，副作用更少。这种对GNP的探索代表了肿瘤学纳米医学发展的创新方向。制备并表征装载Nivolumab的GNP。最佳配方的粒径为191.9±0.67nm，多分散指数为0.027±0.02,药物包封率为54.67±3.51%。共培养实验涉及A549靶细胞和用游离纳武单抗溶液处理的效应Jurkat细胞，和纳武单抗加载的GNP，证明后者在抑制率方面有显著改善,载药GNP评分为87.88±2.47%,游离纳武单抗溶液评分为60.53±3.96%.纳武单抗加载的GNP具有较低的IC50值，0.41±0.01µM，与72h时的游离nivolumab溶液（1.22±0.37µM）相比。结果表明，与nivolumab溶液治疗相比，施用nivolumab负载的GNP通过增强效应Jurkat细胞活性来增强对A549细胞的细胞毒性。
